At the beginning of September, the IVD industry has been full of good news. HOB Biotech Group was approved the issuance and listing(first issue); Beijing Bohui Innovation Biotechnology Co.,Ltd. acquires a total of 50% of ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd. with RMB 24 million in cash; Beijing Leadman Biochemistry Co., Ltd. plans to use its own funds to invest RMB 100 million to establish a wholly-owned subsidiary Guangzhou Leadman Medical Technology Co., Ltd. (tentative name). The Details are as follows:

Bohui：the acquisition of part of the equity of ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd. and its capital increase

In order to further expand the development of the laboratory and testing business, Beijing Bohui Innovation Biotechnology Co.,Ltd. recently signed the "Equity Transfer Agreement on ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd." with shareholders Gao Sheng, Tu Mingyu, and Yang Wanbin of ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd. , to acquire a total of 50% of its shares in ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd. with RMB 24 million in cash; At the same time, Bohui signed the "Capital Increase and Share Expansion Agreement" with the shareholders of ABIOQUANT BIO-MEDCAL TECHNOLOGY Co., Ltd.. The company will subscribe for the new registered capital of ABIOQUANT at RMB 25 million for 1.5625 million yuan. After the capital increase is completed, the company will hold 67.12% of ABIOQUANT. In addition, the company signed the "Equity Continuing Acquisition Agreement" with the shareholders of ABIOQUANT. On the premise that all parties have complied with the aforementioned "Equity Transfer Agreement" and "Capital Increase and Share Expansion Agreement", the company will continue to acquire the shares of ABIOQUANT from old shareholders in accordance with the conditions agreed in the agreement.

After the completion of this transaction, ABIOQUANT will become the company's holding subsidiary and be included in the company's consolidated statement.

Leadman : the establishment of Guangzhou Leadman Medical Technology Co., Ltd.

Recently, due to strategic development needs, Beijing Leadman Biochemistry Co., Ltd. plans to use its own funds to invest RMB 100 million to establish a wholly-owned subsidiary Guangzhou Leadman Medical Technology Co., Ltd. (tentative name).

The establishment of a wholly-owned subsidiary is based on the company’s long-term strategic development planning needs, combined with the development trend of the in vitro diagnostic industry, in order to fully mobilize resources from all parties, achieve synergy and sharing, and further improve the company’s business operation strategy layout, which will help consolidate and enhance the company competitive advantage.

Beijing Leadman Biochemistry Co., Ltd was founded in November 1997. It is a high-tech enterprise focusing on R & D, manufacture, and sales of in vitro diagnostic (IVD) products. Equipped with international management concept, innovative R & D team, high-quality products, nationwide marketing network, and excellent technical services, Leadman has become a highly diversified enterprise with core competencies in biochemistry, in vitro diagnostic reagents and instruments.